After-Hours Movers 10/25: (OGXI) (AKAM) (VRTX) Higher; (EW) (NUVA) (CMG) (AAPL) Lower (more...)

October 25, 2016 6:03 PM EDT

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Today's After-Hours Movers

OncoGenex Pharmaceuticals, Inc. (Nasdq: OGXI) 35% HIGHER; announced positive survival results from the final analysis of the Phase 2 Borealis-2 trial of apatorsen in combination with docetaxel treatment that enrolled 200 patients with metastatic bladder cancer whose disease had progressed following first-line platinum-based chemotherapy. Patients who received apatorsen treatment experienced a 20% reduction in risk of death, compared to patients receiving docetaxel alone (HR=.80; 95% CI: 0.65-0.98; p=0.078). The primary analysis was a superiority test of overall survival, performed at a one-sided 0.10 significance level using a stratified log-rank test. The trial was conducted by the Hoosier Cancer Research Network at 28 sites across the United States.

Edwards Lifesciences (NYSE: EW) 13.8% LOWER; reported Q3 EPS of $0.68, in-line with the analyst estimate of $0.68. Revenue for the quarter came in at $739.4 million versus the consensus estimate of $749.14 million. GUIDANCE: Edwards Lifesciences sees Q4 2016 EPS of $0.67-$0.77, versus the consensus of $0.74. Edwards Lifesciences sees Q4 2016 revenue of $750-790 million, versus the consensus of $801.14 million. Edwards Lifesciences sees FY2016 EPS of $2.82-$2.92, versus the consensus of $2.88. Edwards Lifesciences sees FY2016 revenue of $2.7-3.0 billion, versus the consensus of $2.94 billion.

NuVasive (NASDAQ: NUVA) 12.1% LOWER; reported Q3 EPS of $0.40, in-line with the analyst estimate of $0.40. Revenue for the quarter came in at $239.6 million versus the consensus estimate of $243.52 million. GUIDANCE: NuVasive sees 2016 EPS of $1.64, versus the consensus of $1.65. NuVasive sees 2016 revenue of $954 million, versus the consensus of $962.35 million and prior expectation of $962.0 million.

Weatherford (NYSE: WFT) 10.7% LOWER; reported Q3 EPS of ($0.39), $0.14 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $1.36 billion versus the consensus estimate of $1.44 billion.

Akamai Technologies (NASDAQ: AKAM) 7.5% HIGHER; reported Q3 EPS of $0.68, $0.07 better than the analyst estimate of $0.61. Revenue for the quarter came in at $584.1 million versus the consensus estimate of $571.87 million.

Vertex Pharma (NASDAQ: VRTX) 6.7% HIGHER; reported Q3 EPS of $0.16, $0.02 worse than the analyst estimate of $0.18. Revenue for the quarter came in at $410 million versus the consensus estimate of $418.37 million. Vertex also announced the planned initiation of two Phase 2 studies to evaluate the next-generation correctors VX-440 and VX-152 in triple combination regimens with tezacaftor (VX-661) and ivacaftor in people with cystic fibrosis (CF).

Juniper Networks (NYSE: JNPR) 6.5% HIGHER; reported Q3 EPS of $0.58, $0.06 better than the analyst estimate of $0.52. Revenue for the quarter came in at $1.29 billion versus the consensus estimate of $1.25 billion. GUIDANCE: Juniper Networks sees Q4 2016 EPS of $0.59-$0.64, versus the consensus of $0.60. Juniper Networks sees Q4 2016 revenue of $1.32-1.38 billion, versus the consensus of $1.32 billion.

Pandora (NYSE: P) 6% LOWER; reported Q3 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $351.9 million versus the consensus estimate of $366.33 million. Pandora sees Q4 2016 revenue of $362-374 million, versus the consensus of $392.1 million.

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) 5.6% LOWER; announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are being sold by Collegium. In addition, Collegium has granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.

Panera Bread (NASDAQ: PNRA) 5.4% HIGHER; reported Q3 EPS of $1.37, $0.03 better than the analyst estimate of $1.34. Revenue for the quarter came in at $684.2 million versus the consensus estimate of $680.5 million. Q3 2016 Company-owned comparable net bakery-cafe sales up 3.4%, up 7.2% on a two-year basis. GUIDANCE: Panera Bread sees FY2016 EPS of $6.67-$6.72, versus the consensus of $6.68.

Garmin Ltd. (NASDAQ: GRMN) 5% HIGHER; gained post-market ahead of the release of Q3 results tomorrow morning.

iRobot Corp. (NASDAQ: IRBT) 5% HIGHER; reported Q3 EPS of $0.70, $0.27 better than the analyst estimate of $0.43. Revenue for the quarter came in at $168.6 million versus the consensus estimate of $156.96 million. GUIDANCE: iRobot Corp. sees Q4 2016 EPS of $0.36-$0.44, versus the consensus of $0.60. iRobot Corp. sees Q4 2016 revenue of $202-207 million, versus the consensus of $204.73 million. iRobot Corp. sees FY2016 EPS of $1.36-$1.44, versus the consensus of $1.32. iRobot Corp. sees FY2016 revenue of $650-655 million, versus the consensus of $641.4 million.

Capital One Financial (NYSE: COF) 3.8% LOWER; reported Q3 EPS of $2.03, $0.09 better than the analyst estimate of $1.94. Revenue for the quarter came in at $6.46 billion versus the consensus estimate of $6.42 billion. Chargeoffs rise.

C. H. Robinson Worldwide (NASDAQ: CHRW) 3.5% LOWER; reported Q3 EPS of $0.90, $0.06 worse than the analyst estimate of $0.96. Revenue for the quarter came in at $3.36 billion versus the consensus estimate of $3.33 billion.

NCR Corp. (NYSE: NCR) 3.5% HIGHER; reported Q3 EPS of $0.87, $0.06 better than the analyst estimate of $0.81. Revenue for the quarter came in at $1.68 billion versus the consensus estimate of $1.63 billion. GUIDANCE: NCR Corp. sees FY2016 EPS of $2.97-$3.02, versus prior guidance of $2.90-$3.00 and the consensus of $2.95. NCR Corp. sees FY2016 revenue of $6.47-6.50 billion, versus prior guidance of $6.325-6.400 billion and the consensus of $6.38 billion.

Chipotle Mexican Grill (NYSE: CMG) 2.6% LOWER; reported Q3 EPS of $0.27, $1.32 worse than the analyst estimate of $1.59. Revenue for the quarter came in at $1 billion versus the consensus estimate of $1.09 billion. EPS impairment included $0.29 related to the ShopHouse impairment charge and $0.23 due to the deferral of revenue from Chiptopia. Comps fell 21.9 percent, versus an 18.7 percent drop expected.

Apple (NASDAQ: AAPL) 2.5% LOWER; reported Q4 EPS of $1.67, $0.02 better than the analyst estimate of $1.65. Revenue for the quarter came in at $46.9 billion versus the consensus estimate of $46.89 billion. The company sold 45.51 million iPhone units in the quarter, versus the consensus of 45 million. GUIDANCE: Apple sees Q1 2017 revenue of $76-78 billion, versus the consensus of $74.98 billion.

Express Scripts (NASDAQ: ESRX) 1.3% HIGHER; reported Q3 EPS of $1.74, in-line with the analyst estimate of $1.74. Revenue for the quarter came in at $25.41 billion versus the consensus estimate of $25.49 billion. GUIDANCE: Express Scripts sees FY2016 EPS of $6.36-$6.42, versus prior guidance of $6.33-$6.43 and the consensus of $6.37.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

After-Hours Movers

Add Your Comment